These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 32582532)
1. Prognostic Value of Programmed Cell Death 1 Ligand-1 in Patients With Bone and Soft Tissue Sarcomas: A Systemic and Comprehensive Meta-Analysis Based on 3,680 Patients. Wang F; Yu T; Ma C; Yuan H; Zhang H; Zhang Z Front Oncol; 2020; 10():749. PubMed ID: 32582532 [No Abstract] [Full Text] [Related]
2. Clinicopathological and prognostic significance of PD-L1 expression in sarcoma: A systematic review and meta-analysis. Zheng C; You W; Wan P; Jiang X; Chen J; Zheng Y; Li W; Tan J; Zhang S Medicine (Baltimore); 2018 Jun; 97(25):e11004. PubMed ID: 29923984 [TBL] [Abstract][Full Text] [Related]
3. Prognostic value of programmed death-ligand 1 in sarcoma: a meta-analysis. Zhu Z; Jin Z; Zhang M; Tang Y; Yang G; Yuan X; Yao J; Sun D Oncotarget; 2017 Aug; 8(35):59570-59580. PubMed ID: 28938660 [TBL] [Abstract][Full Text] [Related]
4. The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients. Lu Y; Song Y; Xu Y; Ou N; Liang Z; Hu R; Zhang W; Kang J; Wang X; Liu L; Yang Y; Liu X Transl Androl Urol; 2020 Apr; 9(2):367-381. PubMed ID: 32420142 [TBL] [Abstract][Full Text] [Related]
5. Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis. Zhu L; Sun J; Wang L; Li Z; Wang L; Li Z Front Pharmacol; 2019; 10():962. PubMed ID: 31616289 [No Abstract] [Full Text] [Related]
6. Prognostic Value of Programmed Cell Death 1 Ligand-1 (PD-L1) or PD-1 Expression in Patients with Osteosarcoma: A Meta-Analysis. Huang X; Zhang W; Zhang Z; Shi D; Wu F; Zhong B; Shao Z J Cancer; 2018; 9(14):2525-2531. PubMed ID: 30026851 [No Abstract] [Full Text] [Related]
7. Prognostic and Clinicopathological Value of Programmed Cell Death Ligand1 Expression in Patients With Small Cell Lung Cancer: A Meta-Analysis. Cai H; Zhang H; Jiang Y Front Oncol; 2020; 10():1079. PubMed ID: 32670887 [No Abstract] [Full Text] [Related]
8. Predictive Values of Programmed Cell Death-Ligand 1 Expression for Prognosis, Clinicopathological Factors, and Response to Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Inhibitors in Patients With Gynecological Cancers: A Meta-Analysis. Zhang C; Yang Q Front Oncol; 2020; 10():572203. PubMed ID: 33634012 [TBL] [Abstract][Full Text] [Related]
9. The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis. Xu G; Sun L; Li Y; Xie F; Zhou X; Yang H; Du S; Xu H; Mao Y Front Oncol; 2019; 9():897. PubMed ID: 31620360 [No Abstract] [Full Text] [Related]
10. Prognostic and Clinicopathological Role of PD-L1 in Endometrial Cancer: A Meta-Analysis. Lu L; Li Y; Luo R; Xu J; Feng J; Wang M Front Oncol; 2020; 10():632. PubMed ID: 32426281 [No Abstract] [Full Text] [Related]
11. The Clinicopathologic and Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1) Expression in Patients With Prostate Cancer: A Systematic Review and Meta-Analysis. Li Y; Huang Q; Zhou Y; He M; Chen J; Gao Y; Wang X Front Pharmacol; 2018; 9():1494. PubMed ID: 30733677 [No Abstract] [Full Text] [Related]
12. Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients. Liu X; Shan C; Song Y; Du J Front Oncol; 2019; 9():1111. PubMed ID: 31709181 [No Abstract] [Full Text] [Related]
13. The Prognostic and Clinicopathological Roles of PD-L1 Expression in Colorectal Cancer: A Systematic Review and Meta-Analysis. Li Y; He M; Zhou Y; Yang C; Wei S; Bian X; Christopher O; Xie L Front Pharmacol; 2019; 10():139. PubMed ID: 30873025 [No Abstract] [Full Text] [Related]
14. The clinicopathological significance and prognostic value of programmed death-ligand 1 in prostate cancer: a meta-analysis of 3133 patients. Shen H; Liu J; Sun G; Yan L; Li Q; Wang Z; Xie L Aging (Albany NY); 2020 Dec; 13(2):2279-2293. PubMed ID: 33318295 [TBL] [Abstract][Full Text] [Related]
15. Correlation Between PD-L2 Expression and Clinical Outcome in Solid Cancer Patients: A Meta-Analysis. Yang H; Zhou X; Sun L; Mao Y Front Oncol; 2019; 9():47. PubMed ID: 30891423 [No Abstract] [Full Text] [Related]
16. The clinicopathological and prognostic value of programmed death-ligand 1 in colorectal cancer: a meta-analysis. Ni X; Sun X; Wang D; Chen Y; Zhang Y; Li W; Wang L; Suo J Clin Transl Oncol; 2019 May; 21(5):674-686. PubMed ID: 30392153 [TBL] [Abstract][Full Text] [Related]
17. Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis. Li J; Wang P; Xu Y PLoS One; 2017; 12(6):e0179536. PubMed ID: 28604812 [TBL] [Abstract][Full Text] [Related]
18. Prognostic and clinicopathological value of PD-L1 in colorectal cancer: a systematic review and meta-analysis. Yang L; Xue R; Pan C Onco Targets Ther; 2019; 12():3671-3682. PubMed ID: 31190869 [No Abstract] [Full Text] [Related]
19. Clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with esophageal squamous cell carcinoma: a meta-analysis. Qu HX; Zhao LP; Zhan SH; Geng CX; Xu L; Xin YN; Jiang XJ J Thorac Dis; 2016 Nov; 8(11):3197-3204. PubMed ID: 28066599 [TBL] [Abstract][Full Text] [Related]
20. A pooled analysis of the prognostic value of PD-L1 in melanoma: evidence from 1062 patients. Yang J; Dong M; Shui Y; Zhang Y; Zhang Z; Mi Y; Zuo X; Jiang L; Liu K; Liu Z; Gu X; Shi Y Cancer Cell Int; 2020; 20():96. PubMed ID: 32256205 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]